SPDR MSCI ACWI Climate Paris Aligned ETF (NASDAQ: NZAC)

最新ニュース SPDR MSCI ACWI Climate Paris Aligned ETF (NASDAQ:NZAC)

Technology

Financial Services

Industrials

Healthcare

Consumer Cyclical

Real Estate

Basic Materials

Communication Services

Utilities

Consumer Defensive

Other

Energy

In seeking to track the performance of the MSCI ACWI Climate Paris Aligned Index (the Index), the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index. Instead, the Fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index. The quantity of holdings in the Fund will be based on a number of factors, including asset size of the Fund.

Apple Inc

Microsoft Corp

Nvidia Corp.

Amazon.Com Inc

Alphabet Holding Company Inc.

Meta Platforms, Inc.

Broadcom Inc

Alphabet Inc

Eli Lilly & Co.

Tesla, Inc.

SPDR MSCI ACWI Climate Paris Aligned ETF

111 Equity Group, LLC ("111 Equity") and its principal filed a Schedule 13D with the Securities and Exchange Commission ("SEC") to disclose that 111 Equity and its principal have collectively accumulated a 5.17% stock ownership stake in&nbsp;Matinas Biopharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#NYSE">MTNB</a>) ("MTNB") as of January 2, 2025. Since this filing, the principal of 111 Equity bought more shares to increase 111 Equity's and the principal's collective ownership in MTNB as 111 Equity believes MTNB provides an opportunity for shareholders to enhance shareholder value. MTNB announced the start of a strategic review in late October 2024. 111 Equity believes there are avenues to enhance shareholder value as a part of this strategic review, including, without limitation, monetizing certain existing assets (including the potential asset sale of MAT2203, MTNB's lead Phase 3 ready antifungal drug candidate), leveraging MTNB's value as a listed security on NYSE for potential merger candidates, and leveraging and maintaining MTNB's balance sheet.
As of MTNB's most recent 10-Q (filed on November 13, 2024), MTNB has reported $10,295,000 in cash and cash equivalents which would equate to roughly $2.13 cash per share value, which is below the stock's closing price of $0.55 on January 16, 2025. 111 Equity understands that there has been additional cash burn due to MTNB laying off 80% of the workforce; however, it is 111 Equity's belief that the cash on hand will still be greater than the current market cap of MTNB.&nbsp;

MTNB

111 Equity Group Increases Stake To 5.17% In Matinas Biopharma As Strategic Review Underway Including Asset Sale Of MAT2203; $10.3M Cash Reported Which Would Equate To Roughly $2.13 Cash Per Share Value

Compass Point analyst Giuliano Bologna maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Buy and raises the price target from $31 to $34.

News

Price Target

Analyst Ratings

Compass Point Maintains Buy on SLM, Raises Price Target to $34

Allurion Technologies, Inc. (&quot;Allurion&quot; or the &quot;Company&quot;) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>), a company dedicated to ending obesity, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,240,000 shares of the Company&#39;s common stock at a price of $6.00 per share in a registered direct offering priced at-the-market under NYSE rules.
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 1,240,000 shares of common stock. The warrants have an exercise price of $6.00 per share, will become exercisable immediately following the date of stockholder approval and expire on the fifth anniversary of such approval. The Company also agreed to obtain shareholder approval for the repricing of its outstanding warrants issued in its July 2024 offering of securities for investors in this offering that held such outstanding warrants, reducing the exercise price thereof to $6.00 per share.
Roth Capital Partners is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from this offering are expected to be approximately $7.4 million, before deducting the placement agent&#39;s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about January 27, 2025, subject to the satisfaction of customary closing conditions.

Offerings

ALUR

Allurion Announces Securities Purchase Agreement For 1.24M Shares At $6 Each And Warrants For 1.24M Shares; Plans To Reprice July 2024 Warrants To $6 After Shareholder Approval, Raising ~$7.4M Of Gross Proceeds

Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) has outperformed the market over the past 5 years by 8.4% on an annualized basis producing an average annual return of 21.67%. Currently, Discover Finl has a market capitalization of $50.59 billion. 
Buying $1000 In DFS: If an investor had bought $1000 of DFS stock 5 years ago, it would be worth $2,714.52 today based on a price of $201.31 for DFS at the time of writing.
<h3>Discover Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737729008_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Discover Finl 5 Years Ago Would Be Worth This Much Today

Looking into the current session, Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) shares are trading at $119.05, after a 0.08% drop. Over the past month, the stock fell by 1.89%, but over the past year, it actually spiked by 66.54%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1737729008_0_0.png" alt="Past Year Chart" />

<h3>How Does Trade Desk P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 575.87 in the Media industry, Trade Desk Inc. has a lower P/E ratio of 192.16. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1737729008_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Trade Desk Inc's Price Over Earnings

WISeKey International Holding Ltd ("WISeKey") ((SIX: WIHN, NASDAQ:<a href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>), a leading global cybersecurity, blockchain, and IoT company, today &nbsp;unveiled live on CNBC from Davos, that in conjunction with the preview of the forthcoming book "Humanity at the Crossroads," WISeKey, and SEALSQ, are joining forces with leading organizations and institutions to create a groundbreaking AI platform, codenamed HUMAN-AI-T. This universal AI will harness the wisdom of humanity, derived from certified historical and contemporary resources, to ensure the preservation and application of human knowledge for future generations.
Building on the principles of the Svalbard Global Seed Vault, which secures the world's agricultural biodiversity, the HUMAN-AI-T project aims to serve as the digital equivalent for human knowledge. It will consolidate a vast range of sources, including religious texts, legal frameworks, international treaties, philosophical ideas, and spiritual teachings from civilizations across the globe, integrating these with wisdom and local traditions. By doing so, it will holistically define humanity and teach the AI unique intricacies, ensuring that its development remains centered on universal human values.

LAES

WKEY

WISeKey And SEALSQ Announce AI Platform HUMAN-AI-T; Aims To Consolidate Global Human Wisdom And Preserve Knowledge; To Include Diverse Sources Like Religious, Legal, And Philosophical Texts

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and raises the price target from $501 to $512.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Raises Price Target to $512

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates Triumph Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFIN#NASDAQ">TFIN</a>) with a Underperform and lowers the price target from $85 to $80.

Reiteration

TFIN

Keefe, Bruyette & Woods Reiterates Underperform on Triumph Financial, Lowers Price Target to $80

Barclays analyst Jared Shaw maintains East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) with a Overweight and lowers the price target from $125 to $120.

EWBC

Barclays Maintains Overweight on East West Bancorp, Lowers Price Target to $120

U Power Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) (the "Company" or "U Power"), a vehicle sourcing services provider with a vision to becoming a comprehensive EV battery power solution provider in China, today announced that it has entered into a securities purchase agreement with certain institutional investors to sell 1,041,668 Class A ordinary shares (or pre-funded warrants in lieu thereof) of the Company in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investors warrants to purchase up to 1,562,502 Class A ordinary shares. The combined effective offering price for each Class A ordinary share and accompanying warrant is $4.80. The warrants are immediately exercisable, expire five years from issuance, and have an initial exercise price of $4.80 per share, which exercise price is subject to standard adjustments for dividends, splits and similar events and is also subject to adjustment for certain dilutive issuances (as defined in the form of warrant).
The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $5.0 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.
The offering is expected to close on or about January 27, 2025, subject to the satisfaction of customary closing conditions.

UCAR

U Power Announces Pricing Of $5M Registered Direct Offering

Barclays analyst Jeffrey Bernstein maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Underweight and lowers the price target from $412 to $402.

Barclays Maintains Underweight on Domino's Pizza, Lowers Price Target to $402

Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the LungFit&#xAE; PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspiratory limb of the patient breathing circuit of a ventilator in a way that provides a constant concentration of nitric oxide, as set by the user, to the patient throughout the inspired breath.

XAIR

Beyond Air Announces LungFit PH Market Authorization By Australian TGA As Class IIb Medical Device To Deliver Nitric Oxide

Barclays analyst Terry Ma maintains Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) with a Overweight and raises the price target from $186 to $209.

Barclays Maintains Overweight on Discover Finl, Raises Price Target to $209

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Market Perform and raises the price target from $30 to $32.

Keefe, Bruyette & Woods Maintains Market Perform on SLM, Raises Price Target to $32

PRELIMINARY 2024 FINANCIAL GUIDANCE
<ul>
<li>Revenue: The Company expects to report revenues in the range of USD 300 million to USD 350 million.</li>
<li>Net Income: The Company anticipates net income in the range of USD 11 million to USD 15 million.</li>
<li>EPS: The Company anticipates EPS in the range of USD 2.6 USD 3.6.</li>
<li>Annual Report: Nisun International expects to release its annual report before the end of April 2025.</li>
</ul>

Earnings

Guidance

NISN

Nisun International Projects 2024 Revenue Of $300M-$350M, Net Income $11M-$15M, EPS $2.60-$3.60

Mark Cuban is famous for straightforward financial advice, such as, "Don't use credit cards. If you use a credit card, <a href="https://www.benzinga.com/personal-finance/24/05/39092288/if-you-use-your-credit-card-you-do-not-want-to-be-rich-warns-mark-cuban-on-the-dave-ramsey-show">you don't want to be rich.</a>" It's a message he's shared countless times, from blog posts to chats with financial gurus like Dave Ramsey. But even Cuban couldn't avoid his ironic <a href="https://www.benzinga.com/personal-finance/24/09/40920706/billionaire-mark-cuban-says-his-credit-was-so-bad-radio-shack-denied-him-if-you-use-credit-cards">run-in with a credit card – </a>one that's become the stuff of NBA legend.
It happened in 2011, after his <a href="https://www.benzinga.com/news/25/01/42865308/mark-cuban-on-selling-dallas-mavericks-stake-i-didnt-want-my-kids-feeling-the-pressure-of-walking-in">Dallas Mavericks clinched</a> their first-ever NBA championship by taking down the Miami Heat. Naturally, Cuban wanted to celebrate in style. He and the team headed to LIV nightclub in Miami, where Cuban decided to treat himself to a 15-liter bottle of Armand de Brignac Champagne (aka "Ace of Spades") with a jaw-dropping price tag of $140,000.
Don't Miss:
<ul>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
<li>The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">Here's how to know if your nest egg is keeping pace.</a></li>
</ul>
When it came time to pay, Cuban confidently handed over his American Express Centurion Card, better known as the "Black Card." And then? Declined.
In a 2018 Fox Sports 1's Fair Game interview, Cuban laughed as he retold the story. "I had to go into the back office and call Amex," he said. "They told me, ‘Sir, this hasn't been authorized. It's a new card.'"
Always quick on his feet, Cuban explained the situation to a seemingly unimpressed customer service rep. "I asked to speak to a supervisor and said, ‘Did you see the NBA game tonight? Are you a basketball fan?'" His pitch? Classic Cuban charm. "This is Mark Cuban. We just won the championship. Can I please spend some money?"
David Grutman, the owner of LIV, remembered the chaos, too. "We were in the back because his credit card was denied," he said, shaking his head at how surreal the moment was.
Trending: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
Here's the thing: the Amex Centurion Card is technically not a credit card – it's a charge card. What's the difference? A charge card typically requires you to pay off the balance in full each month, unlike credit cards, which allow you to carry a balance (and rack up interest). Charge cards also don't have a preset spending limit, but that doesn't mean charges won't get flagged based on spending patterns or payment history. So, while Cuban's card might not have had a specific limit, Amex played gatekeeper that night.
The story is even funnier when considering Cuban's longtime stance on credit cards. He's spent years warning people against them, claiming, "<a href="https://www.benzinga.com/personal-finance/24/11/42248381/mark-cuban-insists-credit-cards-are-not-your-friend-and-proposes-taking-out-a-personal-loan-for-expenses-instead-is-this-a-smart-move">The best place to invest</a> is to pay off all your credit cards and burn them. " But to be fair, he also acknowledges credit cards can work – if you pay off the balance in full every month.
Reflecting on the lesson, Cuban has said, "The 18%, 20%, even 30% interest you're paying is going to cost you way more than you could ever earn elsewhere." It's sound advice, even if Cuban once had to plead with Amex to let him <a href="https://www.benzinga.com/money/are-you-rich">splurge on Champagne</a>.
That night might've started with an awkward pause at the register, but it ended with a Champagne toast in true Mark Cuban fashion.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-annuity-adv">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
</ul>

Personal Finance

Mark Cuban's Black Amex Card Got Declined Buying A $140,000 Bottle Of Champagne To Celebrate Team's NBA Win – 'Can I Please Spend Some Money?'

Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) has outperformed the market over the past 20 years by 2.11% on an annualized basis producing an average annual return of 10.62%. Currently, Jones Lang LaSalle has a market capitalization of $12.99 billion. 
Buying $100 In JLL: If an investor had bought $100 of JLL stock 20 years ago, it would be worth $766.10 today based on a price of $273.80 for JLL at the time of writing.
<h3>Jones Lang LaSalle's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737728114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

The earnings results for Meridian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRBK#NASDAQ">MRBK</a>) for Q4 were made public on Friday, January 24, 2025 at 09:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Meridian beat estimated earnings by 44.0%, reporting an EPS of $0.49 versus an estimate of $0.34.
Revenue was up $7.52 million from the same period last year.
<h3>Earnings History Overview</h3>
The company beat on EPS by $0.07 in the last quarter, resulting in a 2.0% increase share price change the following day.
Here's a look at Meridian's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>0.31</td>
<td>0.24</td>
<td>0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.42</td>
<td>0.30</td>
<td>0.24</td>
<td>0.05</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>26.54M</td>
<td>25.67M</td>
<td>24.00M</td>
<td>24.51M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>29.07M</td>
<td>26.17M</td>
<td>24.59M</td>
<td>25.06M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Meridian <a href="https://www.benzinga.com/quote/MRBK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MRBK

Meridian Earnings Report: Q4 Overview

Keefe, Bruyette &amp; Woods analyst Timothy Switzer reiterates Live Oak Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOB#NYSE">LOB</a>) with a Market Perform and lowers the price target from $48 to $44.

Keefe, Bruyette & Woods Reiterates Market Perform on Live Oak Bancshares, Lowers Price Target to $44

Barclays analyst Brandon Oglenski maintains CSX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) with a Overweight and lowers the price target from $40 to $38.

Comments

SPDR MSCI ACWI Climate Paris Aligned ETF

ニュース

最新ニュース SPDR MSCI ACWI Climate Paris Aligned ETF (NASDAQ:NZAC)

ニュース

パートナーシップ

ベンジンガ・グローバル